Pangene Corp., of Fremont, Calif., appointed Tony Fong as director of sales and marketing.
Perlegen Sciences Inc., of Santa Clara, Calif., added Vern Norviel as general counsel and corporate secretary.
PharmaNetics Inc., of Raleigh, N.C., appointed Mark Triscott vice president of research and development.
Ricerca LLC, of Concord, Ohio, added David Stout as director of medicinal chemistry.
Structural GenomiX Inc., of San Diego, appointed Bill Rutter and Stelios Papadopoulos to its board.
Targacept Inc., of Winston-Salem, N.C., added Tamar Howson and Mark Skaletsky to its board.
Telik Inc., of South San Francisco, appointed Graeme Martin chief technical officer.
Variagenics Inc., of Cambridge, Mass., promoted Edward Koval to vice president, corporate and strategic development and Mark Adams to vice president, bioinformatics. Also, it hired James Aswell as senior director, diagnostics.
Vertex Pharmaceuticals Inc., of Madison, Wis., said its subsidiary, PanVera Corp., named Michael Wokasch president.
ViaCell Inc., of Boston, added Kurt Gunter as senior vice president of clinical and regulatory affairs and government relations; named Robert Koshgarian vice president, operations; and added Christoph Adams as senior vice president, business development.
Visible Genetics Inc., of Toronto, added Heather Munroe-Blum to its board and added Brendan Larder as chief scientific officer.
Xechem International Inc., of New Brunswick, N.J., elected John Luther, Jed Goldart and Neil Kosterman to its board.
Xencor Inc., of Monrovia, Calif., added William Radany as chief business officer and Joyce Morrison as vice president, intellectual property.
Xenon Genetics Inc., of Vancouver, British Columbia, appointed Parag Saxena to its board.